Evolus is a medical aesthetics company whose lead product candidate is an injectable purified botulinum toxin type A complex that would compete with Botox, the lead product from Allergan’s (NYSE: AGN) stable. Evolus disclosed that it had filed its S-1 for a $75 million IPO.

The company is being spun out of its parent, ALPHAEON, which has funded all operations to date. According to the filing, ALPHAEON is a technology company focused on providing healthcare products and services, including patient financing services.